Anil Nanda, MD
Allergy & Immunology · Dallas, TXNPI 1568461192
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (34.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.7%.
Across 260 payments — averaging $133.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- Sanofi$5K
- GSK$5K
- Pfizer$5K
- AstraZeneca$3K
- Aquestive Therapeutics, Inc.$2K
- plus $5K from 22 others
Across 10 payments — averaging $5176.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$19K
- GSK$17K
- AbbVie$16K
What the payments were for
- Consulting fees$11,82834%
- Speaking & faculty fees$10,39530%
- Travel & lodging$1,0313%
- Food & beverage$11,34833%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 34 | $8,223 |
| Sanofi | 30 | $5,486 |
| GSK | 59 | $5,246 |
| Pfizer | 3 | $5,199 |
| AstraZeneca | 48 | $2,846 |
| Aquestive Therapeutics, Inc. | 2 | $2,254 |
| Regeneron Healthcare Solutions, Inc. | 22 | $2,137 |
| Genentech USA, Inc. | 11 | $559 |
| Alk-abello, Inc | 8 | $479 |
| Pharming Healthcare, Inc. | 2 | $260 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $216 |
| Boehringer Ingelheim | 2 | $213 |
| ADMA Biomanufacturing LLC | 1 | $160 |
| Galderma Laboratories, L.p. | 3 | $154 |
| Amgen | 9 | $152 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $139 |
| Blueprint Medicines Corporation | 2 | $135 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Biocryst Pharmaceuticals, Inc. | 1 | $123 |
| Lilly USA, LLC | 1 | $110 |
| Biocryst US Sales Co., LLC | 1 | $110 |
| Optinose US, Inc. | 1 | $104 |
| Incyte Corporation | 1 | $94 |
| Mimedx Group, Inc. | 1 | $42 |
| Phadia US Inc. | 1 | $33 |
| Genentech, Inc. | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,667 in reported general payments places this provider in the 85th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 85 | $257,526 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $49,363 |
| Dupixent SyringeDupilumab | 12 | $44,087 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,581 |
| Spiriva RespimatTiotropium Bromide | 29 | $16,935 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $10,883 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,392 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $3,444 |
| Epinephrine | 20 | $3,340 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $1,989 |
| Ipratropium Bromide | 77 | $1,961 |
| Azelastine Hcl | 53 | $1,685 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $773 |
| Fluticasone Propionate | 25 | $253 |
| Montelukast Sodium | 46 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $30 | $257,52685 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $5,246 | $56,75585 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,846 | $31,46467 claims |
| Boehringer IngelheimSpiriva Respimat | $213 | $16,93529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Dallas
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lara GrossDallas$171K
- Sonak DaulatDallas$72K
- Joseph WestDallas$39K
- Joseph DiazSan Antonio$1.1M
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Bobby LanierBenbrook$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.